TipRanks

Notifications

Tag: KNSA

Total 70 Posts

Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on G1 Therapeutics (GTHXResearch Report) and Kiniksa Pharmaceuticals (KNSAResearch Report) with bullish sentiments.

G1 Therapeutics (GTHX)

In a report released today, Gil Blum from Needham reiterated a Buy rating on G1 Therapeutics, with a price target of $12.00. The company’s shares closed last Wednesday at $3.19.

According to TipRanks.com, Blum is a 4-star analyst with an average return of 8.4% and a 44.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Recursion Pharmaceuticals, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for G1 Therapeutics with a $8.33 average price target, implying a 226.7% upside from current levels. In a report issued on February 13, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Kiniksa Pharmaceuticals (KNSA)

Goldman Sachs analyst Paul Choi maintained a Buy rating on Kiniksa Pharmaceuticals today and set a price target of $32.00. The company’s shares closed last Wednesday at $19.95, close to its 52-week high of $20.94.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 10.3% and a 57.7% success rate. Choi covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, PTC Therapeutics, and Ascendis Pharma.

Kiniksa Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $27.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GTHX: